Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches

Solutions to Avoid False Positives for Rituximab in Pre-Transplant Crossmatches

Rituximab (anti-CD20) is commonly used as immunotherapy against B cells, in the context of pre-transplant crossmatches, where the presence of rituximab in the tested sera with donor cells can alter their results both by flow cytometry (FCXM) as complement-dependent cytotoxicity (CDCXM) giving rise t...

Full description

Bibliographic Details
Main Authors: Argentina Colmenero Velazquez, Ignacio Iturrieta-Zuazo, Juan Luis Valdivieso Shephard, Marisa Di Natale, Claudia Rita, Rubén Ballester González, José Luis Castañer Alabau, Israel Nieto Gañán
Format: Article
Language:English
Published: MDPI AG 2020-08-01
Series:Antibodies
Subjects:
rituximab
organ transplantation
crossmatches
false positives
Online Access:https://www.mdpi.com/2073-4468/9/3/41

Internet

https://www.mdpi.com/2073-4468/9/3/41

Similar Items